CHOICE OF THERAPEUTIC STRATEGY IN SEZARY SYNDROME: CASE REPORT


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The article presents the modern concept of treatment of Sezary syndrome, discusses the choice of the optimal therapeutic algorithm; also own authors’ observation is provided. Sezary syndrome is a leukemic variant of epidermotropic T-cell skin lymphoma, which is clinically manifested by generalized erythema, macrolaminar desquamation and visceral pathology. This relatively rare dermatosis is characterized by often poor clinical response to treatment and poor prognosis without adequate treatment. Cases of complete recovery or long-term remission in patients with Sezary syndrome are rare casuistically A clinical case of Sezary syndrome in 52-year-old patient is described.

Texto integral

Acesso é fechado

Sobre autores

D. Zaslavsky

SPbSPMU

Department of dermatology

A. Yunovidova

NWSMU n.a. I.I. Mechnikov

Department of dermatology

P. Wolkenstein

Dermatology Service of the Henri Mondor University Hospital

A. Sydikov

SPbSPMU

Department of dermatology

S. Skrek

NWSMU n.a. I.I. Mechnikov; French Clinic of Skin Diseases n.a. Pierre Wolkenstein

Teaching Assistant at the Department of Dermatovenerology

A. Kovalchuk

Dermatovenerologic Dispensary №11 of the Central District of St. Petersburg

A. Sobolev

SRI of Medical Mycology n.a. P.N. Kashkin NWSMU .a. I.I. Mechnikov

G. Salogub

FSPbSMU n.a. Acad. I.P. Pavlov

Department of Faculty Therapy with course of Endocrinology, Cardiology and Functional Diagnostics n.a. G.F. Lang with the Clinic

Bibliografia

  1. Scarisbrick J.J., Kim Y.H., Whittaker S.J., Wood G.S., Vermeer M.H., Prince H.M., Quagiino P. Prognostic factors, prognostic indices and staging in mycosis fungoides and Sézary syndrome: where are we now? Br. J. Dermatol. 2014;6:1226-36.
  2. Whittaker S.J., Marsden J.R., Spittle M., Jones R.R. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T-cell lymphomas. Br. J. Dermatol. 2003; 149:1095-107.
  3. Girardi M., Edelson R.L., Cutaneous T-Cell Lymphoma: Pathogenesis and Treatment. 0ncology.2000;14:1061-70.
  4. Trautingera F., Knoblera R., Willemzeb R., Perisc K., Stadlerd R., Larochee L., D'incanf M., Rankig A., Pimpinellih N., Ortiz-Romeroi P., Dummerj R., Estrachk T., Whittakerl S. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. Eur. J. Cancer. 2006;42:1014-30.
  5. Olsen E.A., Rook A.H., Zic J., Kim Y., Porcu P., Querfeld C., Wood G., Demierre M.F., Pittelkow M., Wilson L.D., Pinter-Brown L., Advani R., Parker S., Kim E.J., Junkins-Hopkins J.M., Foss F., Cacchio P., Duvic M. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). J Am. Acad. Dermatol. 2011;64:352-404.
  6. Stadler R., Kremer A. Therapeutic advances in cutaneous T-cell lymphoma (CTCL): from retinoids to rexinoids. Semin. Oncol. 2006; 33:7-10.
  7. Ashworth J., Booker J., Breathnach S.M. Effects of topical corticosteroid therapy on Langerhans cell antigen presenting function in human skin. Br. J. Dermatol. 1988;118:457-70.
  8. Herrmann J.J., Roenigk H.H. Jr., Honigsmann H. Ultraviolet radiation for treatment of cutaneous T-cell lymphoma. Hematol. Oncol. Clin. North Am.1995;9:1077-88.
  9. Thomsen K., Hammar H., Molin L., Volden G. Retinoids plus PUVA (Re-PUVA) and PUVA in mycosis fungoides, plaque stage: a report from the Scandinavian mycosis fungoides group. Acta Derm. Venereol. 1989; 69:536-38.
  10. Lowe N.J., Cripps D.J., Dufton P.A., Vickers C.F Photochemotherapy for mycosis fungoides: a clinical and histological study. Arch. Dermatol. 1979;115:50-3.
  11. Mangelsdorf D.J., Umesono K., Evans R.M. The retinoid receptors. in: The Retinoids, Biology, Chemistry and Medicine. New York: Raven Press. 1994;2:319-50.
  12. Farooqui A.A., Antony P., Ong W.Y., Horrocks L.A., Freysz L. Retinoic acid-mediated phospholipase A2 signaling in the nucleus. Brain Res. Rev. 2004;45:179-95.
  13. Dunn L.K., Gaar L.R., Yentzer B.A., O'Neill J.L., Feldman S.R. Acitretin in dermatology: a review. J. Drugs Dermatol. 2011;10:772-82.
  14. Cheeley J., Sahn R.E., DeLong L.K., Parker S.R. Acitretin for the treatment of cutaneous T-cell lymphoma. J. Am. Acad. Dermatol. 2013;68:247-54.
  15. Sokoiowska-Wojdyto M., Lugowska-Umer H., Maciejewska-Radomska A. Oral retinoids and rexinoids in cutaneous T-cell lymphomas. Postepy Dermatol. Alergol. 2013;30:19-29.
  16. Ларина С.Н., Чебышев Н.В., Ших Е.В., Каркищенко В.Н. Модулирование действия ядерных рецепторов и регуляция биотрансформации веществ. Биомедицина. 2009;1:70-80.
  17. Beylot-Barry M. Bexarotène: Targretin. Ann. Dermatol. Venerol. 2007;134:987-91.
  18. Bagot M., Bensussan A. Les lymphomes T épidermotropes comme modèles de progression tumorale. Med. Sci. 2006;22:192-96.
  19. Bagot M. Les lymphomes cutanés. Paris: Springer, 2013. P 77-91.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2016

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies